U.S. markets open in 8 hours 54 minutes

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
29.79-0.87 (-2.84%)
At close: 4:00PM EST

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 89927 0
http://www.morphosys.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees640

Key Executives

NameTitlePayExercisedYear Born
Dr. Jean-Paul KressChairman of Management Board, MD & CEON/AN/A1965
Dr. Malte Peters M.D.Chief R&D Officer and Member of the Management BoardN/AN/A1962
Mr. Roland Wandeler Ph.D.COO & Member of Management BoardN/AN/A1972
Mr. Klaus De WallHead of Accounting & TaxN/AN/AN/A
Ms. Lara Smith WeberHead of Controlling, Corp. Fin. & Corp. Devel.N/AN/AN/A
Dr. Margit UrbanHead of Discovery Alliances & TechnologiesN/AN/AN/A
Dr. Anja PomrehnSr. VP & Head of Investor RelationsN/AN/AN/A
Dr. Armin WeidmannHead of Compliance and Quality AssuranceN/AN/AN/A
Ms. Charlotte LohmannSr. VP & Gen. CounselN/AN/A1970
Mr. Thomas BiegiVP & Head of Corp. CommunicationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Corporate Governance

MorphoSys AG’s ISS Governance QualityScore as of January 22, 2021 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.